Oric Pharmaceuticals (ORIC)

• Market cap: $579M
• 1 day: 6.76%
• 5 days: -0.85%
• 1 month: -6.06%
• 3 months: -27.02%
• 6 months: 17.12%
• Year to date: -10.18%
• 1 year: -3.75%
• 5 years: -68.14%
• 10 years: -68.14%
• Sector: Healthcare
• Industry: Pharmaceutical Preparations

About: ORIC Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It has a pipeline of therapies designed to counter resistance mechanisms in cancer by leveraging its expertise within three specific areas: hormone-dependent cancers, precision oncology, and key tumor dependencies. The company has product candidates namely ORIC-944, ORIC-114, and ORIC-533.

Employees: 112

Fund manager confidence

Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)

1,838% more call options, than puts

Call options by funds: $155K | Put options by funds: $8K

67% more first-time investments, than exits

New positions opened: 25 | Existing positions closed: 15

49% more capital invested

Capital invested by funds: $481M [Q2] → $715M (+$234M) [Q3]

9% more funds holding

Funds holding: 112 [Q2] → 122 (+10) [Q3]

0% more funds holding in top 10

Funds holding in top 10: 4 [Q2] → 4 (+0) [Q3]

0% more repeat investments, than reductions

Existing positions increased: 38 | Existing positions reduced: 38

1.88% less ownership

Funds ownership: 100.87% [Q2] → 98.99% (-1.88%) [Q3]

Research analyst outlook

3 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $17 107% upside
• Avg. target: $19.33 135% upside
• High target: $21 156% upside

3 analyst ratings

• positive: 3 100%
• neutral: 0 0%
• negative: 0 0%

HC Wainwright & Co. Robert Burns 23% 1-year accuracy 36 / 155 met price target	156% upside $21	Buy Reiterated	4 Nov 2024
Wells Fargo	144% upside $20	Overweight Initiated	31 Oct 2024
Jones Trading Soumit Roy 27% 1-year accuracy 3 / 11 met price target	107% upside $17	Buy Initiated	31 Oct 2024